Clinical features and outcomes of plasma cell leukemia: a single-institution experience in the era of novel agents
{{output}}
Plasma cell leukemia (PCL) is a rare hematologic malignancy with aggressive clinical and biologic features. Data regarding its prognosis with the use of the novel agents, i.e., the immunomodulatory drugs thalidomide and lenalidomide, and the proteasome inhibit... ...
